Warning! GuruFocus detected
1 Severe warning sign
with GLUE.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Monte Rosa Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US61225M1027
Description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.71 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.59 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -0.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 29.6 | |||||
| 3-Year EPS without NRI Growth Rate | 30.7 | |||||
| 3-Year Book Growth Rate | -21.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -22.06 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.2 | |||||
| 9-Day RSI | 38.24 | |||||
| 14-Day RSI | 41.83 | |||||
| 3-1 Month Momentum % | -18.01 | |||||
| 6-1 Month Momentum % | 4.9 | |||||
| 12-1 Month Momentum % | -31.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | |||||
| Quick Ratio | 2.4 | |||||
| Cash Ratio | 2.37 | |||||
| Days Sales Outstanding | 43.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | 0.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -107.26 | |||||
| Net Margin % | -96.14 | |||||
| FCF Margin % | 50.26 | |||||
| ROE % | -36.91 | |||||
| ROA % | -21.79 | |||||
| ROIC % | -72.55 | |||||
| 3-Year ROIIC % | -6.55 | |||||
| ROC (Joel Greenblatt) % | -134.59 | |||||
| ROCE % | -30.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 27.39 | |||||
| PS Ratio | 6.06 | |||||
| PB Ratio | 1.56 | |||||
| Price-to-Tangible-Book | 1.56 | |||||
| Price-to-Free-Cash-Flow | 24.45 | |||||
| Price-to-Operating-Cash-Flow | 19.55 | |||||
| EV-to-EBIT | -0.36 | |||||
| EV-to-Forward-EBIT | -0.16 | |||||
| EV-to-EBITDA | -0.4 | |||||
| EV-to-Forward-EBITDA | -0.16 | |||||
| EV-to-Revenue | 0.39 | |||||
| EV-to-Forward-Revenue | 2.24 | |||||
| EV-to-FCF | 0.77 | |||||
| Price-to-Net-Current-Asset-Value | 2.16 | |||||
| Price-to-Net-Cash | 2.23 | |||||
| Earnings Yield (Greenblatt) % | -277.78 | |||||
| FCF Yield % | 10.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLUE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Monte Rosa Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 75.622 | ||
| EPS (TTM) ($) | -1.032 | ||
| Beta | 1.08 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.07 | ||
| Volatility % | 97.8 | ||
| 14-Day RSI | 41.83 | ||
| 14-Day ATR ($) | 0.582561 | ||
| 20-Day SMA ($) | 6.1295 | ||
| 12-1 Month Momentum % | -31.68 | ||
| 52-Week Range ($) | 3.21 - 12.4 | ||
| Shares Outstanding (Mil) | 61.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Monte Rosa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Monte Rosa Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Monte Rosa Therapeutics Inc Frequently Asked Questions
What is Monte Rosa Therapeutics Inc(GLUE)'s stock price today?
The current price of GLUE is $5.67. The 52 week high of GLUE is $12.40 and 52 week low is $3.21.
When is next earnings date of Monte Rosa Therapeutics Inc(GLUE)?
The next earnings date of Monte Rosa Therapeutics Inc(GLUE) is 2025-05-09 Est..
Does Monte Rosa Therapeutics Inc(GLUE) pay dividends? If so, how much?
Monte Rosa Therapeutics Inc(GLUE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers